Corteva Guides FY 2026 EPS to $0.76-$0.80, Far Below $1.07 Consensus

By Sophie Lindqvist

Corteva (NYSE:CTVA) on Wednesday issued fiscal year 2026 earnings guidance of $0.760 to $0.800 per share, well below the consensus analyst estimate of $1.070. The agricultural science company delivered the range as an update to its prior FY 2026 outlook.

The market barely reacted. Shares rose $0.03 in midday trading on Wednesday to reach $12.20, on volume of 12,838,632 shares against an average of 8,011,878.

What does the guidance miss mean?

The new range sits roughly 25 percent under the Street's number. That is a wide gap for a company of Corteva's profile, and it arrives alongside valuation metrics that suggest the market has already repriced the stock.

The shares trade at a price-to-earnings ratio (a measure of price relative to annual profit) of 8.08 and a PEG ratio (P/E adjusted for expected growth) of 1.69. The beta, at 0.58, indicates the stock moves far less than the broader market.

Technical indicators tell a harsher story. The 50-day moving average price stands at $41.93, and the 200-day moving average at $70.50, both far above the current quote. The stock has touched a one-year low of $11.24 and a one-year high of $90.97. Market capitalization is $8.14 billion.

How deep is the dividend cut?

Deep. Corteva declared a quarterly dividend of $0.05 per share, down 72 percent from its previous $0.18. The dividend is payable on Tuesday, December 15, to investors of record on Tuesday, December 1, which is also the ex-dividend date.

The reduced payout annualizes to $0.20 per share, a yield of 1.6 percent. The dividend payout ratio (the share of earnings paid out as dividends) is 13.25 percent. Balance-sheet measures remain unremarkable: a quick ratio of 1.10, a current ratio (short-term assets over short-term liabilities) of 1.52, and a debt-to-equity ratio of 0.07.

Where do analysts stand?

The analyst community is split, though not evenly. According to MarketBeat data, sixteen analysts rate the stock a Buy, six a Hold, and one a Sell, producing a consensus rating of Moderate Buy and an average target price of $60.59.

Recent moves span a remarkable range:

• Bank of America raised its price objective from $90.00 to $96.00 with a buy rating on Monday, July 20.
• UBS Group cut its target to $15.00 and set a neutral rating on Monday, October 12.
• KeyCorp upgraded the stock from sector weight to overweight with a $17.00 target on Wednesday, October 7.
• Royal Bank of Canada reiterated an outperform rating and a $17.00 target, also on Wednesday, October 7.
• Weiss Ratings downgraded Corteva from hold (c+) to hold (c) on Monday, August 3.

An average target of $60.59 against a $12.20 share price implies extraordinary upside, or extraordinary staleness in some targets. The Bank of America figure, in particular, predates the October repricing evident in the UBS and KeyCorp notes. Readers may draw their own conclusions.

What does Corteva actually do?

The company develops and supplies products and services for farmers, focused on seeds and crop protection. Its seed portfolio includes corn, soybean, and other crop varieties sold under the Pioneer and Brevant brands. Crop protection offerings span herbicides, insecticides, fungicides, and biological products, alongside digital tools that support farm decision-making.

For a company trading at a fraction of its moving averages, the guidance and the dividend cut together suggest management is prioritizing balance-sheet conservatism over shareholder distributions. The consensus will now decide whether the $1.07 estimate survives contact with the new range. History suggests it will not.